Pac Małgorzata
Oddział Immunologii, Instytut "Pomnik-Centrum Zdrowia Dziecka" w Warszawie.
Pol Merkur Lekarski. 2011 Jun;30(180):413-6.
Primary antibody deficiency (PAD) is the most common form of primary immunodeficiency (PID), and presents up to 60-70% of PID. The hallmark of PAD are low antibody level and recurrent infections. Patients require life-long immunoglobulin replacement therapy. Now they can be treated either with intravenous (IVIG) or subcutaneous (SCIG) immunoglobulin. The last one is indicated in patients with unacceptable adverse reactions to the intravenous immunoglobulin preparations, with poor vein access or willing to improve the quality of their life. Several data and clinical trials proved that SCIG therapy is at least as safe and efficacious as IVIG to prevent infections in patients with PAD.
原发性抗体缺陷（PAD）是原发性免疫缺陷（PID）最常见的形式，占PID的60%-70%。PAD的标志是抗体水平低和反复感染。患者需要终身免疫球蛋白替代治疗。目前，他们可以接受静脉注射免疫球蛋白（IVIG）或皮下注射免疫球蛋白（SCIG）治疗。后者适用于对静脉注射免疫球蛋白制剂有不可接受的不良反应、静脉通路不佳或希望改善生活质量的患者。多项数据和临床试验证明，在预防PAD患者感染方面，SCIG治疗至少与IVIG一样安全有效。
